{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:53:11Z","timestamp":1767649991603,"version":"build-2065373602"},"reference-count":64,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":796,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is a slow\u2010growing hematologic malignancy and the most common type of leukemia in the western world. The lifetime risk for developing CLL is 1 in 216 men and women. Unfortunately, CLL is considered incurable with the chemotherapeutic agents available today. Bendamustine is a new agent that was recently added to the available regimens for the treatment of CLL. It was also recently approved for the treatment of non\u2010Hodgkin's lymphoma. Its mechanism of action is unknown, but it contains an alkylating group similar to that of other bifunctional alkylating agents such as chlorambucil, and it also contains a benzimidazole central ring thought to exhibit antipurine\u2010like properties. The United States Food and Drug Administration approved bendamustine based on results from an international phase III study of CLL in which bendamustine was compared with chlorambucil in treatment\u2010na\u00efve patients. Ongoing clinical trials are assessing the utility of bendamustine in combination with other agents for the treatment of CLL, as well as for other malignancies.<\/jats:p>","DOI":"10.1592\/phco.29.11.1375","type":"journal-article","created":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T14:24:23Z","timestamp":1256567063000},"page":"1375-1384","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bendamustine: A New Treatment Option for Chronic Lymphocytic Leukemia"],"prefix":"10.1002","volume":"29","author":[{"given":"Ashley E.","family":"Glode","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Anthony","family":"Jarkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology. Non\u2010Hodgkin's lymphomas. Available fromhttp:www.nccn.org. Accessed March 29 2009."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402651"},{"key":"e_1_2_1_4_2","unstructured":"National Cancer Institute.Surveillance epidemiology and end results stat fact sheets.Cancer: chronic lymphocytic leukemia. Available fromhttp:seer.cancer.govstatfactshtmlclyl.html. Accessed December 1 2008."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.5.770"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3729"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2043.2043","article-title":"Bendamustine versus chlorambucil in treatment\u2010naive patients with B\u2010cell chronic lymphocytic leukemia (B\u2010CLL): results of an international phase III study [abstract]","volume":"110","author":"Knauf WU","year":"2007","journal-title":"Blood"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"},{"issue":"11","key":"e_1_2_1_13_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.lba-1.lba-1","article-title":"Rituximab, fludarabine, and cyclophosphamide (R\u2010FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III reach trial [abstract]","volume":"112","author":"Robak T","year":"2008","journal-title":"Blood"},{"issue":"11","key":"e_1_2_1_14_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.325.325","article-title":"Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression\u2010free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract]","volume":"112","author":"Hallek M","year":"2008","journal-title":"Blood"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3836"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-033274"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0762"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61125-8"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701724801"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.10.3052"},{"key":"e_1_2_1_22_2","unstructured":"Cephalon Inc.Cephalon receives FDA approval for Treanda a novel chemotherapy for chronic lymphocytic leukemia [news release].March 20 2008. Available fromhttp:www.cephalon.commedianews\u2010releasesarticlecephalon\u2010receives\u2010fda\u2010approval\u2010for\u2010treanda\u2010a\u2010novel\u2010chemotherapy\u2010for\u2010chronic\u2010lymphocytic\u2010leukemia. Accessed December 2 2008."},{"key":"e_1_2_1_23_2","unstructured":"National Cancer Institute.FDA approval for bendamustine hydrochloride. Available fromhttp:www.cancer.govcancertopicsdruginfofda\u2010bendamustine\u2010hydrochloride. Accessed March 29 2009."},{"key":"e_1_2_1_24_2","first-page":"1013","article-title":"IMET 3393, gamma\u2010(1\u2010methyl\u20105\u2010bis([beta]\u2010chlor\u00e4thyl)\u2010amino\u2010benzimidazoyl(2)\u2010butters\u00e4ure\u2010hydrochlorid, ein neus Zytostatikum aus der Reihe der Benzimidazol\u2010Loste","volume":"110","author":"Ozegowski W","year":"1971","journal-title":"Zbl Pharm"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34872"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"e_1_2_1_28_2","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high\u2010dose chemotherapy","volume":"90","author":"Knop S","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0074-4"},{"key":"e_1_2_1_30_2","first-page":"1357","article-title":"Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I\/II study of the German CLL study group","volume":"90","author":"Bergmann MA","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000175587.31940.19"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.09.029"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.JTO.0000263714.46449.4c"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1061"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199606000-00007"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161050-00009"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00305a014"},{"key":"e_1_2_1_38_2","first-page":"904","article-title":"Laboratory evaluation of a new nitrogen mustard, 2\u2010[di\u2010(2\u2010chlorethyl0 aminomethyl] benzimidazole and of other 2\u2010chlorethyl compounds","volume":"17","author":"Hirschberg E","year":"1957","journal-title":"Cancer Res"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2787(72)90282-1"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.11.757"},{"key":"e_1_2_1_41_2","unstructured":"Developmental Therapeutics Program National Cancer Institute National Institutes of Health.Screening services: DTP human tumor cell line screen. Available fromhttp:dtp.nci.nih.govbranchesbtbivclsp.html. Accessed March 29 2009."},{"volume-title":"Treanda (bendamustine hydrochloride) package insert","year":"2008","author":"Cephalon Inc.","key":"e_1_2_1_42_2"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.2217\/14796694.4.3.323"},{"key":"e_1_2_1_44_2","first-page":"458","article-title":"Pharmacokinetics of bendamustine in patients with malignant tumors [abstract]","volume":"14","author":"Matthias M","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_45_2","first-page":"782","article-title":"Pharmacokinetics of bendamustine (Cytostasan) in patients","volume":"40","author":"Preiss R","year":"1985","journal-title":"Pharmazie"},{"key":"e_1_2_1_46_2","first-page":"1267","article-title":"Untersuchungen zur plasmaeiweiBbinding von bendamustine (Cytostasan) und ambazon","volume":"45","author":"Haase D","year":"1990","journal-title":"Z Klin Med"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022855"},{"key":"e_1_2_1_48_2","unstructured":"FlockhartDA.Cytochrome P450 drug\u2010interaction table. Available fromhttp:www.medicine.iupui.eduflockhart. Accessed December 2 2008."},{"key":"e_1_2_1_49_2","first-page":"76","article-title":"Get to know an enzyme: CYP1A2","author":"Horn JP","year":"2007","journal-title":"Pharmacy Times"},{"key":"e_1_2_1_50_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2091.2091","article-title":"Bendamustine versus chlorambucil as first\u2010line treatment in B cell chronic lymphocytic leukemia: an updated analysis from an international phase III study [abstract]","volume":"112","author":"Knauf WU","year":"2008","journal-title":"Blood"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2319"},{"key":"e_1_2_1_53_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.330.330","article-title":"Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG) [abstract]","volume":"112","author":"Fischer K","year":"2008","journal-title":"Blood"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0023-2"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701361828"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701694194"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm378"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22846"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200412000-00001"},{"key":"e_1_2_1_60_2","unstructured":"National Institutes of Health.ClinicalTrials.gov. Available fromhttp:www.clinicaltrials.gov. Accessed December 1 2008."},{"key":"e_1_2_1_61_2","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology. Antiemesis. Available fromhttp:www.nccn.org. Accessed December 1 2008."},{"key":"e_1_2_1_62_2","article-title":"Bendamustine is an efficient and well tolerated option in the palliation of pretreated B\u2010cell chronic lymphatic leukemias (CLL) [abstract]","volume":"20","author":"Aviado M","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200110000-00003"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320000180"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0050-z"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.29.11.1375","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.29.11.1375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:52:34Z","timestamp":1761069154000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.29.11.1375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1592\/phco.29.11.1375"],"URL":"https:\/\/doi.org\/10.1592\/phco.29.11.1375","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}